埃索美拉唑疗效如何

(Nexium) is the left-handed isomer of omeprazole and a new generation of proton pump inhibitors. Among proton pump inhibitors, it has the strongest effect on inhibiting gastric acid secretion. Compared with omeprazole, esomeprazole (Nexium) is less affected by the metabolic enzyme CYP2C19 and is suitable for people with rapid metabolism and patients who need to take clopidogrel at the same time. Today we will learn more about the efficacy of esomeprazole?

In a clinical comparative study of esomeprazole (Nexium) and omeprazole in the treatment of reflux esophagitis, the total effective rate of esomeprazole was 97.18%, which was significantly higher than 84.51% of omeprazole, and there was no significant difference in the incidence of adverse reactions. Chen Caiming has done a cost-effectiveness analysis of omeprazole and esomeprazole in the treatment of duodenal ulcer. The recovery rate of the esomeprazole (Nexium) group was 92.6%, which was higher than the 78.6% of omeprazole. The results proved that esomeprazole has cost and effectiveness advantages.

The results of a randomized clinical trial using cimetidine as the positive control showed that during the treatment evaluation period, the esomeprazole (Nexium) group had a lower rate of upper gastrointestinal bleeding than the cimetidine group (2.7% in the esomeprazole group and 4.6% in the cimetidine group). Esomeprazole 40 mg twice a day can effectively prevent upper gastrointestinal bleeding in severe patients. The safety profile of the esomeprazole group was similar to that of the cimetidine group. It was generally well tolerated among severe Chinese patients and no new safety issues were found. 

In addition, esomeprazole (Nexium) has also been approved for 1. Gastroesophageal reflux disease (GERD). 2. Treatment of erosive reflux esophagitis. 3. Long-term maintenance treatment to prevent recurrence of cured esophagitis patients. 4. Symptom control of gastroesophageal reflux disease (GERD) combined with appropriate antimicrobial therapy to eradicate Helicobacter pylori. 5. Heal duodenal ulcers associated with Helicobacter pylori infection. 6. Prevent the recurrence of peptic ulcers related to Helicobacter pylori.

In 2000, the oral formulation of esomeprazole (Nexium) was first launched in Sweden. In 2001, it was approved by the FDA for marketing in the United States. On July 30, 2020, AstraZeneca announced that the China National Medical Products Administration (NMPA) officially approved Nexium (esomeprazole sodium) injection for the prevention of stress ulcer bleeding in severe patients.

The above is the content of (Nexium) effect, I hope it can help you!

Recommended related hot articles: /newsDetail/71930.html